Biogen Idec has stopped making Tysabri - 500 Beiträge pro Seite

[Cyberhexe]

Biogen hat die Produktion von Tysabri nun doch eingestellt!!!!


http://www.boston.com/business/technology/biotechnology/arti…

But even though Biogen Idec has stopped making Tysabri at its North Carolina plant, Mullen did sound hopeful about its eventual return. ``If we didn`t think this was coming back, why would we spend $30 million just to complete this investigation?" he said.

Tysabri may have a chance because it has proven so effective against MS. Two-year data released last month by the American Academy of Neurology underscored the drug`s ability to slow the progression of multiple sclerosis and prevent relapses.

``People write to me saying, `I`ll sign whatever waiver you want to give me, let me take this drug, it changed my life,` " said Mullen. Results of the internal investigation are due this summer. The company will then approach the FDA for discussions. His comments suggested it might seek to reintroduce Tysabri to a smaller, more targeted patient population.

[jojobada]

http://www.boston.com/business/technology/biotechnology/arti… Aber, obwohl Biogen Idec gestoppt hat, Tysabri an seinem Nord-Carolina Betrieb zu bilden, klang Mullen über seine etwaige Rückkehr hoffnungsvoll. ` `, wenn wir nicht dachten, daß dieses zurückkam, warum würden wir $30 Million gerade aufwenden, um diese Untersuchung durchzuführen?" er sagte. Tysabri kann eine Wahrscheinlichkeit haben, weil es geprüft hat, also wirkungsvoll gegen zweijährige Daten des MS freigegebener letzter Monat durch die amerikanische Akademie von Neurologie die Fähigkeit der Droge unterstrich, die Weiterentwicklung der mehrfachen Sklerose zu verlangsamen und Rückfälle zu verhindern. ` ` schreiben Leute mir sagend, ` ich unterzeichne was Aufhebung Sie mich geben wünschen, lassen Sie mich diese Droge nehmen, änderte sie mein Leben, ` "sagte Mullen. Resultate der internen Untersuchung sind dieser Sommer passend. Die Firma nähert dann sich der FDA für Diskussionen. Seine Anmerkungen schlugen vor, daß sie suchen konnte, Tysabri zu einer kleineren, gerichteteren geduldigen Bevölkerung wieder einzuführen.

[jojobada]

Bitte das nächste mal die ganze nachricht reinstellen.

Danke

Mullen takes the long view
May 4, 2005

Page 2 of 2 -- For instance, Mullen said, while investors and the media have focused on the Tysabri problems in recent weeks, few noticed the company`s disclosure of pivotal trials showing the cancer treatment Rituxan helped patients with rheumatoid arthritis. The findings could allow the company to expand into new territory.

ADVERTISEMENT

In the three months that Tysabri was on the market, about 5,000 MS patients took the drug. Some reported remarkable reversals in their disease, more dramatic than what they experienced with Biogen`s Avonex or similar drugs on the market. And many patients still want Tysabri, even though a third patient in a trial for Crohn`s disease was posthumously diagnosed with the fatal disease associated with it, progressive multifocal leukoencephalopathy.

While Kelly Martin, chief executive of Elan Corp., has made several optimistic predictions about Tysabri`s return, Mullen`s more cautious remarks suit some biotech fund managers just fine.

``Biogen Idec has been very conservative in their guidances," said Sven Borho, general partner at OrbiMed Advisors LLC, which manages several biotech-focused funds. ``I want a management that underpromises and overdelivers."

But even though Biogen Idec has stopped making Tysabri at its North Carolina plant, Mullen did sound hopeful about its eventual return. ``If we didn`t think this was coming back, why would we spend $30 million just to complete this investigation?" he said.

Tysabri may have a chance because it has proven so effective against MS. Two-year data released last month by the American Academy of Neurology underscored the drug`s ability to slow the progression of multiple sclerosis and prevent relapses.

``People write to me saying, `I`ll sign whatever waiver you want to give me, let me take this drug, it changed my life,` " said Mullen. Results of the internal investigation are due this summer. The company will then approach the FDA for discussions. His comments suggested it might seek to reintroduce Tysabri to a smaller, more targeted patient population.

Adam Walsh, senior vice president and biotechnology analyst at Jefferies & Co. Inc., said the risk of contracting progressive multifocal leukoencephalopathy means Tysabri would return as a niche drug.

``If the drug comes back -- and I think there is a less than 25 percent chance the drug comes back at all -- you`re looking at a severely restricted prescribing label and a possible controlled distribution method," Walsh said. He said that would mean $300 million in annual sales, which Biogen Idec would have to split with Elan, compared to earlier projections of $1.6 billion a year within three years.

Nevertheless, Mullen said Biogen Idec`s immediate plans haven`t changed.

``The meeting I just came from was the same meeting I would have been in eight weeks ago, on business and business development opportunities," he said. ``You can`t panic because you`ve hit a pothole in the road."

Jeffrey Krasner can be reached at [e-mail].

© Copyright 2005 Globe Newspaper Company.

[Rudili]

#Cyberhexe
Aufgrund deiner Behauptung:Biogen hat die Produktion von Tysabri nun doch eingestellt!!!!
habe ich meine Aktien schnellstmöglich verkauft, da ich kein Englisch kann und dein Posting nicht kontrollieren konnte! Das Verbreiten von Falschmeldungen ist hier strafbar und werde ich nicht so hinnehmen.Mir ist ein Schaden im dreistelligen Bereich entstanden und du kannst mich über Boardmail kontaktieren!

[Cyberhexe]

Rudili du Schlaumeier...ich halte es fast schon für fahrlässig an englischsprachigen Märkten zu spekulieren ohne auch nur ein Wort Englisch zu können...mein Anliegen war eigentlich zu recherchieren und meiner Meinung nach verlässliche Info an die Boardteilnehmer weiterzugeben, insbesondere zu Elan...aber weisst du was, mit solchen Dubelis wie du einer bist möchte ich meine Zeit zukünftig nicht mehr vergeuden, weshalb ich mich von diesem Board verabschieden möchte.

Gute Geschäfte zukünftig insbesondere dem fleissigen Zeni
wünscht
ch